<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/1999/REC-html401-19991224/loose.dtd">
<html><head><title>Report for cutaneous-pre-no_benefit 1440013996144 [GSEA]</title><link href='xtools.css' rel='stylesheet'><link href='http://www.broadinstitute.org/gsea/images/XBench.gif' rel='shortcut icon'></head><body><div class='richTable'><table cols='11' border='1'><th class='richTable'></th><th class='richTable'>GS<br> follow link to MSigDB</th><th class='richTable'>GS DETAILS</th><th class='richTable'>SIZE</th><th class='richTable'>ES</th><th class='richTable'>NES</th><th class='richTable'>NOM p-val</th><th class='richTable'>FDR q-val</th><th class='richTable'>FWER p-val</th><th class='richTable'>RANK AT MAX</th><th class='richTable'>LEADING EDGE</th><tr><td class='lessen'>1</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_WNT_BETA_CATENIN_SIGNALING'>HALLMARK_WNT_BETA_CATENIN_SIGNALING</a></td><td><a href='HALLMARK_WNT_BETA_CATENIN_SIGNALING.html'>Details ...</a></td><td>35</td><td>-0.48</td><td>-1.66</td><td>0.009</td><td>0.042</td><td>0.080</td><td>2245</td><td>tags=29%, list=16%, signal=34%</td></tr><tr><td class='lessen'>2</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_IL6_JAK_STAT3_SIGNALING'>HALLMARK_IL6_JAK_STAT3_SIGNALING</a></td><td><a href='HALLMARK_IL6_JAK_STAT3_SIGNALING.html'>Details ...</a></td><td>65</td><td>-0.35</td><td>-1.40</td><td>0.054</td><td>0.321</td><td>0.725</td><td>2745</td><td>tags=32%, list=20%, signal=40%</td></tr><tr><td class='lessen'>3</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_ALLOGRAFT_REJECTION'>HALLMARK_ALLOGRAFT_REJECTION</a></td><td><a href='HALLMARK_ALLOGRAFT_REJECTION.html'>Details ...</a></td><td>137</td><td>-0.32</td><td>-1.40</td><td>0.029</td><td>0.217</td><td>0.733</td><td>3600</td><td>tags=38%, list=26%, signal=51%</td></tr><tr><td class='lessen'>4</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MYOGENESIS'>HALLMARK_MYOGENESIS</a></td><td><a href='HALLMARK_MYOGENESIS.html'>Details ...</a></td><td>118</td><td>-0.30</td><td>-1.30</td><td>0.056</td><td>0.339</td><td>0.950</td><td>3154</td><td>tags=33%, list=23%, signal=42%</td></tr><tr><td class='lessen'>5</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MITOTIC_SPINDLE'>HALLMARK_MITOTIC_SPINDLE</a></td><td><a href='HALLMARK_MITOTIC_SPINDLE.html'>Details ...</a></td><td>196</td><td>-0.27</td><td>-1.21</td><td>0.087</td><td>0.533</td><td>0.998</td><td>2300</td><td>tags=21%, list=16%, signal=25%</td></tr><tr><td class='lessen'>6</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_DN'>HALLMARK_KRAS_SIGNALING_DN</a></td><td><a href='HALLMARK_KRAS_SIGNALING_DN.html'>Details ...</a></td><td>54</td><td>-0.31</td><td>-1.15</td><td>0.246</td><td>0.664</td><td>1.000</td><td>2271</td><td>tags=26%, list=16%, signal=31%</td></tr><tr><td class='lessen'>7</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_APICAL_JUNCTION'>HALLMARK_APICAL_JUNCTION</a></td><td><a href='HALLMARK_APICAL_JUNCTION.html'>Details ...</a></td><td>136</td><td>-0.26</td><td>-1.14</td><td>0.214</td><td>0.631</td><td>1.000</td><td>3330</td><td>tags=35%, list=24%, signal=45%</td></tr><tr><td class='lessen'>8</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION'>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a></td><td><a href='HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION.html'>Details ...</a></td><td>158</td><td>-0.25</td><td>-1.11</td><td>0.248</td><td>0.655</td><td>1.000</td><td>3319</td><td>tags=33%, list=24%, signal=43%</td></tr><tr><td class='lessen'>9</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_UV_RESPONSE_DN'>HALLMARK_UV_RESPONSE_DN</a></td><td><a href='HALLMARK_UV_RESPONSE_DN.html'>Details ...</a></td><td>127</td><td>-0.24</td><td>-1.03</td><td>0.422</td><td>0.859</td><td>1.000</td><td>2774</td><td>tags=28%, list=20%, signal=34%</td></tr><tr><td class='lessen'>10</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_ANGIOGENESIS'>HALLMARK_ANGIOGENESIS</a></td><td><a href='HALLMARK_ANGIOGENESIS.html'>Details ...</a></td><td>25</td><td>-0.31</td><td>-1.00</td><td>0.466</td><td>0.897</td><td>1.000</td><td>342</td><td>tags=12%, list=2%, signal=12%</td></tr><tr><td class='lessen'>11</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_COMPLEMENT'>HALLMARK_COMPLEMENT</a></td><td><a href='HALLMARK_COMPLEMENT.html'>Details ...</a></td><td>141</td><td>-0.22</td><td>-0.97</td><td>0.542</td><td>0.911</td><td>1.000</td><td>3303</td><td>tags=26%, list=24%, signal=34%</td></tr><tr><td class='lessen'>12</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_NOTCH_SIGNALING'>HALLMARK_NOTCH_SIGNALING</a></td><td><a href='HALLMARK_NOTCH_SIGNALING.html'>Details ...</a></td><td>29</td><td>-0.28</td><td>-0.94</td><td>0.539</td><td>0.933</td><td>1.000</td><td>3658</td><td>tags=38%, list=26%, signal=51%</td></tr><tr><td class='lessen'>13</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_TGF_BETA_SIGNALING'>HALLMARK_TGF_BETA_SIGNALING</a></td><td><a href='HALLMARK_TGF_BETA_SIGNALING.html'>Details ...</a></td><td>51</td><td>-0.24</td><td>-0.88</td><td>0.666</td><td>1.000</td><td>1.000</td><td>1227</td><td>tags=12%, list=9%, signal=13%</td></tr><tr><td class='lessen'>14</td><td><a href='http://cancerimmunity.org/peptide/tumor-specific/'>CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS</a></td><td><a href='CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS.html'>Details ...</a></td><td>2</td><td>-0.56</td><td>-0.86</td><td>0.707</td><td>1.000</td><td>1.000</td><td>2460</td><td>tags=50%, list=18%, signal=61%</td></tr><tr><td class='lessen'>15</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_PI3K_AKT_MTOR_SIGNALING'>HALLMARK_PI3K_AKT_MTOR_SIGNALING</a></td><td><a href='HALLMARK_PI3K_AKT_MTOR_SIGNALING.html'>Details ...</a></td><td>86</td><td>-0.21</td><td>-0.84</td><td>0.771</td><td>0.992</td><td>1.000</td><td>2910</td><td>tags=23%, list=21%, signal=29%</td></tr><tr><td class='lessen'>16</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V2'>HALLMARK_MYC_TARGETS_V2</a></td><td><a href='HALLMARK_MYC_TARGETS_V2.html'>Details ...</a></td><td>58</td><td>-0.21</td><td>-0.79</td><td>0.824</td><td>1.000</td><td>1.000</td><td>679</td><td>tags=10%, list=5%, signal=11%</td></tr><tr><td class='lessen'>17</td><td><a href='http://cancerimmunity.org/peptide/overexpressed/'>CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS</a></td><td><a href='CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS.html'>Details ...</a></td><td>27</td><td>-0.23</td><td>-0.76</td><td>0.798</td><td>1.000</td><td>1.000</td><td>2101</td><td>tags=26%, list=15%, signal=30%</td></tr><tr><td class='lessen'>18</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY'>HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY</a></td><td><a href='HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY.html'>Details ...</a></td><td>44</td><td>-0.20</td><td>-0.72</td><td>0.898</td><td>0.994</td><td>1.000</td><td>2519</td><td>tags=23%, list=18%, signal=28%</td></tr><tr><td class='lessen'>19</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_APICAL_SURFACE'>HALLMARK_APICAL_SURFACE</a></td><td><a href='HALLMARK_APICAL_SURFACE.html'>Details ...</a></td><td>29</td><td>-0.19</td><td>-0.63</td><td>0.951</td><td>0.987</td><td>1.000</td><td>3426</td><td>tags=28%, list=25%, signal=36%</td></tr><caption class='table'>Table: Gene sets enriched in phenotype <b>cutaneous-pre-no_benefit (3 samples)<b>&nbsp<a href='gsea_report_for_cutaneous-pre-no_benefit_1440013996144.tsv'>[plain text format]</a></caption></table></div><br></body></html>
